Educational Events & Programs

On June 15, 2017, the National Comprehensive Cancer Network® (NCCN®) hosted a summit focused on current oncology patient safety issues and access considerations under the new administration. The summit provided an opportunity for a varied group of stakeholders including providers, payers, patients, patient advocacy organizations, and industry, to thoughtfully discuss patient access to high quality, effective, and efficient oncology care, as well as to disseminate advances in oncology patient safety systems best practices, processes, and policies. The summit also explored shifting healthcare priorities under the Trump administration and any implications for safety and access to high quality cancer care.

This article was published in the October 2017 edition of the Journal of the National Comprehensive Cancer Network―JNCCN.

Please check back often for additional updates regarding the summit. If you have any questions, please contact Katy Winckworth-Prejsnar.

Supported by Adaptive Biotechnologies; AmerisourceBergen; Apobiologix, a division of ApoPharma USA, Inc.; EMD Serono, Inc.; Gilead Sciences, Inc.; HELSINN; Incyte Corporation; Kite Pharma; Janssen Oncology; National Decision Support Company; and Pharmacyclics LLC, An AbbVie Company. Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc.; Boston Biomedical, Inc.; Celgene Corporation; and Dendreon. This activity is supported by an educational donation provided by Amgen. Supported by AstraZeneca through its NCCN Corporate Council Membership. Supported by an unrestricted grant from Eisai. This activity is supported by a contribution from Lilly. Supported by an independent educational grant from Merck & Co., Inc. Supported by an unrestricted sponsorship from TESARO.